Hugel Inc (145020) - Total Liabilities

Latest as of December 2025: ₩96.68 Billion KRW ≈ $65.52 Million USD

Based on the latest financial reports, Hugel Inc (145020) has total liabilities worth ₩96.68 Billion KRW (≈ $65.52 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Hugel Inc to assess how effectively this company generates cash.

Hugel Inc - Total Liabilities Trend (2014–2025)

This chart illustrates how Hugel Inc's total liabilities have evolved over time, based on quarterly financial data. Check Hugel Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Hugel Inc Competitors by Total Liabilities

The table below lists competitors of Hugel Inc ranked by their total liabilities.

Company Country Total Liabilities
Galapagos N.V.
AS:GLPG
Netherlands €1.25 Billion
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
China CN¥2.76 Billion
Sanquan Food Co Ltd
SHE:002216
China CN¥3.04 Billion
Hunan Corun New Energy Co Ltd
SHG:600478
China CN¥7.30 Billion
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
China CN¥436.33 Million
UIE PLC
CO:UIE
Denmark Dkr121.46 Million
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
China CN¥1.49 Billion
Carabao Group Public Company Limited
BK:CBG-R
Thailand ฿4.93 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Hugel Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hugel Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hugel Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hugel Inc (2014–2025)

The table below shows the annual total liabilities of Hugel Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩96.68 Billion
≈ $65.52 Million
-1.98%
2024-12-31 ₩98.63 Billion
≈ $66.84 Million
-34.06%
2023-12-31 ₩149.57 Billion
≈ $101.36 Million
-41.95%
2022-12-31 ₩257.67 Billion
≈ $174.62 Million
+10.75%
2021-12-31 ₩232.65 Billion
≈ $157.66 Million
+10.96%
2020-12-31 ₩209.67 Billion
≈ $142.09 Million
+7.42%
2019-12-31 ₩195.19 Billion
≈ $132.28 Million
+2.44%
2018-12-31 ₩190.55 Billion
≈ $129.13 Million
+52.17%
2017-12-31 ₩125.22 Billion
≈ $84.86 Million
+201.71%
2016-12-31 ₩41.50 Billion
≈ $28.13 Million
+61.33%
2015-12-31 ₩25.73 Billion
≈ $17.43 Million
-41.58%
2014-12-31 ₩44.04 Billion
≈ $29.84 Million
--

About Hugel Inc

KQ:145020 Korea Biotechnology
Market Cap
$1.85 Billion
₩2.73 Trillion KRW
Market Cap Rank
#6550 Global
#172 in Korea
Share Price
₩252500.00
Change (1 day)
-3.99%
52-Week Range
₩214000.00 - ₩388000.00
All Time High
₩388000.00
About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more